Graham Baker - Smith Nephew Chief Financial Officer, Executive Director
SNN Stock | USD 25.36 0.98 3.72% |
Director
Mr. Graham Baker is Chief Financial Officer, Executive Director of the Company. He joined the Board as Chief Financial Officer in March 2017. He is based in London, UK. Career and experience Graham holds an MA degree in Economics from Cambridge University and qualified as a Chartered Accountant and Chartered Tax Adviser with Arthur Andersen. In 1995, he joined AstraZeneca PLC where he worked for 20 years, holding multiple senior roles, including Vice President Finance Chief Financial Officer, North America, Vice President, Global Financial Services and Vice President, Finance, International 20132015 with responsibility for all emerging markets. Most recently, Graham was Chief Financial Officer of generic pharmaceuticals company Alvogen. Skills and competencies Graham has deep sector knowledge and has had extensive exposure to established and emerging markets which is extremely relevant to his role at Smith Nephew. He has a strong track record of delivering operational excellence and has relevant experience across major finance roles and geographic markets, leading large teams responsible for significant budgets. since 2017.
Age | 50 |
Tenure | 7 years |
Address | Building 5, Watford, United Kingdom, WD18 8YE |
Phone | 44 1923 477 100 |
Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has Return on Asset of 0.0427 % which means that on every $100 spent on assets, it made $0.0427 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0502 %, implying that it generated $0.0502 on every 100 dollars invested. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of March 2024, Return On Capital Employed is likely to drop to 0.12. In addition to that, Return On Assets is likely to drop to 0.03. At this time, Smith Nephew's Total Assets are very stable compared to the past year. As of the 29th of March 2024, Non Current Assets Total is likely to grow to about 6.3 B, while Other Current Assets are likely to drop about 87.4 M.Similar Executives
Showing other executives | DIRECTOR Age | ||
Wesley Schack | Edwards Lifesciences Corp | 74 | |
Paul LaViolette | Edwards Lifesciences Corp | 63 | |
Barbara McNeil | Edwards Lifesciences Corp | 74 | |
William Link | Edwards Lifesciences Corp | 73 | |
Steven Loranger | Edwards Lifesciences Corp | 69 | |
Mark Foletta | DexCom Inc | 57 | |
Richard Collins | DexCom Inc | 61 | |
Gary Jacobs | Motus GI Holdings | 59 | |
Eitan Machover | Medigus Ltd ADR | 55 | |
Yuval Yanai | Medigus Ltd ADR | 65 | |
Aviel Shapira | Medigus Ltd ADR | 61 | |
Ramona Sequeira | Edwards Lifesciences Corp | 55 | |
Kieran Gallahue | Edwards Lifesciences Corp | 57 | |
Erez Haimovitz | Medigus Ltd ADR | N/A | |
Ori Hershkovitz | Medigus Ltd ADR | 39 | |
Eric Topol | DexCom Inc | 63 | |
John Cardis | Edwards Lifesciences Corp | 73 | |
Yair Rabinovitch | Medigus Ltd ADR | 67 | |
Martha Marsh | Edwards Lifesciences Corp | 72 | |
Anat Naschitz | Medigus Ltd ADR | N/A | |
Jay Skyler | DexCom Inc | 71 |
Management Performance
Return On Equity | 0.0502 | ||||
Return On Asset | 0.0427 |
Smith Nephew SNATS Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Friedman, Non-Executive Independent Director | ||
Helen Barraclough, Company Counsel | ||
Gunthorp Oie, IR Contact Officer | ||
Roland Diggelmann, Chief Executive Officer, Executive Director | ||
Helen Maye, Chief Human Resources Officer | ||
Vinita Bali, Non-Executive Independent Director | ||
Simon Fraser, President - Advanced Wound Management and Global Commercial Operations | ||
Massimiliano Colella, President Europe - Middle East and Africa | ||
Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee | ||
Graham Baker, Chief Financial Officer, Executive Director | ||
Cathy ORourke, Chief Legal and Compliance Officer | ||
Ian Melling, Interim Chief Financial Officer | ||
Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
Joe Metzger, Senior Communications | ||
Rick Medlock, Non-Executive Independent Director | ||
Glenn Warner, President - Advanced Wound Management | ||
Paul Connolly, President Operations | ||
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
Angie Risley, Non-Executive Independent Director | ||
Mark Gladwell, President - Global Operations and Global Business Services | ||
John Ma, Non-Executive Independent Director | ||
Vasant Padmanabhan, President - Research & Development | ||
Joseph Papa, Non-Executive Independent Director | ||
Susan Swabey, Company Secretary | ||
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
Philip Cowdy, Chief Officer | ||
Ian Barlow, Non-Executive Independent Director | ||
Namal Nawana, Chief Executive Officer, Executive Director | ||
Bob White, Non-Executive Independent Director | ||
Diogo MoreiraRato, President - Europe and Canada | ||
Alison Parkes, Chief Officer | ||
Skip Kiil, President - Orthopedics | ||
Erik Engstrom, Non-Executive Independent Director | ||
Deepak Nath, Chief Executive Officer | ||
Matthew Stober, President - Global Operations | ||
Marc Owen, Non-Executive Independent Director | ||
AnneFrancoise Nesmes, Chief Financial Officer, Executive Director | ||
Rodrigo Bianchi, Interim President - Asia Pacific | ||
Brian Larcombe, Senior Independent Non-Executive Director | ||
Elga Lohler, Chief Human Resource Officer | ||
Bradley Cannon, President Orthopaedics | ||
Katarzyna MazurHofsaess, Non-Executive Independent Director | ||
Cyrille Petit, Chief Corporate Development Officer | ||
Julie Brown, CFO, Director and Member of Disclosures Committee | ||
Peter Coenen, President - EMEA Region | ||
Robin Freestone, Senior Non-Executive Independent Director | ||
Virginia Bottomley, Non-Executive Independent Director | ||
Myra Eskes, President - Asia Pacific | ||
Andrew Swift, Vice Relations | ||
Michael Frazzette, President - Advanced Surgical Devices | ||
Ingeborg Oie, VP, Investor Relations | ||
Gordon Howe, President of Global Operations | ||
John Campo, Chief Legal Officer | ||
Brad Cannon, President - Sports Medicine & ENT | ||
Jo Hallas, Non-Executive Director | ||
Catheryn ORourke, Chief Legal and Compliance Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0502 | ||||
Return On Asset | 0.0427 | ||||
Profit Margin | 0.05 % | ||||
Operating Margin | 0.14 % | ||||
Current Valuation | 14.3 B | ||||
Shares Outstanding | 437.16 M | ||||
Shares Owned By Insiders | 0.03 % | ||||
Shares Owned By Institutions | 7.58 % | ||||
Number Of Shares Shorted | 2.22 M | ||||
Price To Earning | 25.42 X |
Currently Active Assets on Macroaxis
When determining whether Smith Nephew SNATS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Smith Nephew's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Smith Nephew Snats Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Smith Nephew Snats Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew SNATS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Smith Stock analysis
When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Smith Nephew's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Smith Nephew. If investors know Smith will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Smith Nephew listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.983 | Dividend Share 0.375 | Earnings Share 0.6 | Revenue Per Share 2.5484 | Quarterly Revenue Growth 0.076 |
The market value of Smith Nephew SNATS is measured differently than its book value, which is the value of Smith that is recorded on the company's balance sheet. Investors also form their own opinion of Smith Nephew's value that differs from its market value or its book value, called intrinsic value, which is Smith Nephew's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Smith Nephew's market value can be influenced by many factors that don't directly affect Smith Nephew's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Smith Nephew's value and its price as these two are different measures arrived at by different means. Investors typically determine if Smith Nephew is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Smith Nephew's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.